Background: Lung cancer remains a major global health problem, which causes millions of deaths annually. Because the prognosis is mainly determined by the stage of lung cancer, precise early diagnosis is of great significance to improve the survival and prognosis. Circulating tumor DNA (ctDNA) has been recognized as a sensitive and specific biomarker for the detection of early- and late-stage lung cancer, and next-generation sequencing (NGS) of ctDNA has been accepted as a noninvasive tool for early identification and monitoring of cancer mutations. This study aimed to assess the value of NGS-based ctDNA analysis in detecting gene mutations in lung cancer patients.
Methods: A total of 101 subjects with pathological diagnosis of lung cancer were enrolled, and blood samples were collected. ctDNA samples were prepared and subjected to NGS assays.
Results: There were 31 cases harboring 40 gene mutations, and EGFR was the most frequently mutated gene (27.72%). In addition, there were seven cases with double mutations and one case with triple mutations, with EGFR p.T790M mutation exhibiting the highest frequency.
Conclusion: Our findings demonstrate that NGS of ctDNA is effective in detecting gene mutations in lung cancer patients, and may be used as a liquid biopsy for lung cancer, which facilitates the development of precision treatment regimens for lung cancer.
Keywords: circulating tumor DNA; ctDNA; gene mutation; lung cancer; next-generation sequencing.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Cell-free Circulating Tumor DNA Supplementing Tissue Biopsies for Identification of Targetable Mutations: Implications for Precision Medicine and Considerations for Reconciling ResultsJK Hicks et al. Lung Cancer 111, 135-138. PMID 28838384. - Case ReportsCell-free circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is emerging as a noninvasive technique for detecting targetable mutations. We describe two lung a …
Identification and Monitoring of Somatic Mutations in Circulating Cell-Free Tumor DNA in Lung Cancer PatientsI Francaviglia et al. Lung Cancer 134, 225-232. PMID 31319985.The presented study investigated lung cancer ctDNA analysis, comparing conventional methods versus NGS sequencing, and demonstrated the successful use of plasma ctDNA as …
Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective StudyN Pécuchet et al. PLoS Med 13 (12), e1002199. PMID 28027313.In this study of patients with newly diagnosed NSCLC, we found that ctDNA detection using targeted NGS was associated with poor prognosis. The heterogeneity of lung cance …
Circulating DNA in EGFR-mutated Lung CancerAP Singh et al. Ann Transl Med 5 (18), 379. PMID 29057239. - ReviewCirculating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identific …
Droplet-based Digital PCR and Next Generation Sequencing for Monitoring Circulating Tumor DNA: A Cancer Diagnostic PerspectiveM Postel et al. Expert Rev Mol Diagn 18 (1), 7-17. PMID 29115895. - ReviewEarly detection of cancers through the analysis of ctDNA could have a significant impact on morbidity and mortality of cancer patients. However, using ctDNA for early can …
- Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–485. - PubMed
- Fitzmaurice C, Allen C, Barber RM, et al. Global Burden of Disease Cancer CollaborationGlobal, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–548. - PMC - PubMed
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. - PubMed
- WHO . World Cancer Report 2014. Geneva: World Health Organization; 2014.
- Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1–19. - PubMed